CN104684889A - 二甲双胍的三盐形式 - Google Patents

二甲双胍的三盐形式 Download PDF

Info

Publication number
CN104684889A
CN104684889A CN201380046842.4A CN201380046842A CN104684889A CN 104684889 A CN104684889 A CN 104684889A CN 201380046842 A CN201380046842 A CN 201380046842A CN 104684889 A CN104684889 A CN 104684889A
Authority
CN
China
Prior art keywords
compound
metformin
subject
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380046842.4A
Other languages
English (en)
Chinese (zh)
Inventor
B.L.米拉里
F.C.夏沃利诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi Disi Pharmaceutical Co
Original Assignee
Xi Disi Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by Xi Disi Pharmaceutical Co filed Critical Xi Disi Pharmaceutical Co
Publication of CN104684889A publication Critical patent/CN104684889A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380046842.4A 2012-07-10 2013-07-10 二甲双胍的三盐形式 Pending CN104684889A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US61/669763 2012-07-10
US201261670376P 2012-07-11 2012-07-11
US201261670368P 2012-07-11 2012-07-11
US61/670368 2012-07-11
US61/670376 2012-07-11
US13/841970 2013-03-15
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (1)

Publication Number Publication Date
CN104684889A true CN104684889A (zh) 2015-06-03

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380046842.4A Pending CN104684889A (zh) 2012-07-10 2013-07-10 二甲双胍的三盐形式

Country Status (12)

Country Link
EP (1) EP2872483A4 (https=)
JP (1) JP2015523382A (https=)
KR (1) KR20150036235A (https=)
CN (1) CN104684889A (https=)
AU (1) AU2013290168A1 (https=)
BR (1) BR112015000368A2 (https=)
CA (1) CA2878819A1 (https=)
IL (1) IL236613A0 (https=)
IN (1) IN2015KN00076A (https=)
MX (1) MX2015000408A (https=)
WO (1) WO2014011814A1 (https=)
ZA (1) ZA201500274B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114349665A (zh) * 2021-11-30 2022-04-15 青岛博创生物科学研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
CA2951923A1 (en) * 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US6372790B1 (en) * 1998-02-12 2002-04-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
CN101855204A (zh) * 2007-09-21 2010-10-06 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
DK2229158T3 (en) * 2007-12-20 2016-12-12 Fertin Pharma As Compressed chewing gum tablet
JPWO2009151116A1 (ja) * 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EA201370099A1 (ru) * 2010-10-19 2013-11-29 Элселикс Терапьютикс, Инк. Терапия на основе лигандов хемосенсорных рецепторов
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8853259B2 (en) * 2013-02-07 2014-10-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372790B1 (en) * 1998-02-12 2002-04-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
CN101855204A (zh) * 2007-09-21 2010-10-06 韩兀生物制药株式会社 N,n-二甲基亚氨二羰酸二酰胺二羧酸盐、其制备方法及其药物组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114349665A (zh) * 2021-11-30 2022-04-15 青岛博创生物科学研究院 二甲双胍焦谷氨酸晶体及其制备方法与应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Also Published As

Publication number Publication date
WO2014011814A1 (en) 2014-01-16
IL236613A0 (en) 2015-02-26
ZA201500274B (en) 2017-10-25
EP2872483A1 (en) 2015-05-20
AU2013290168A1 (en) 2015-02-05
MX2015000408A (es) 2015-07-14
BR112015000368A2 (pt) 2017-06-27
IN2015KN00076A (https=) 2015-07-31
CA2878819A1 (en) 2014-01-16
KR20150036235A (ko) 2015-04-07
JP2015523382A (ja) 2015-08-13
EP2872483A4 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
CN104684889A (zh) 二甲双胍的三盐形式
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
AU2012205547B2 (en) Lipid-lowering antidiabetic agent
US8933124B2 (en) Tri-salt form of metformin
JP2010535158A (ja) Ｓ−アリルシステインまたはそのアナローグの使用およびそれらの医薬組成物
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
US20120295973A1 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
TW516959B (en) Composition containing ascorbic acid
US9382187B2 (en) Tri-salt form of metformin
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
CN104557944B (zh) 一种降糖药物及其制备方法
WO2014008379A2 (en) Diamine and meglumine salt forms of fatty acids
US8440723B2 (en) Metformin salts of salicylic acid and its congeners
KR20100016512A (ko) 심근경색증 치료를 위한 철 킬레이터의 용도
US20060004096A1 (en) Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
RU2538221C1 (ru) Способ лечения неалкогольного жирового гепатоза при сахарном диабете 2 типа
US20080280985A1 (en) Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
US20130317034A1 (en) Combination therapy for treating diabetes
US20260000703A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
RU2537227C1 (ru) Гепатопротектор для лечения неалкогольного жирового гепатоза при сахарном диабете 2 типа
JP2021024826A (ja) 糖化産物生成抑制剤及び医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20171117